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wnherited Long QT
yndromes: Be Mindful
f the Potassium Level
anagement of inherited channelopathies has benefited a great
eal from advances in our understanding of the pathophysiological
asis of associated arrhythmogenesis. The hereditary long-QT
yndrome (LQTS) is no exception, being one of the most studied
f the inherited channelopathies. Mechanistically, alterations in
he balance of membrane ion currents can affect action potential
epolarization, hence predisposing to lethal arrhythmias. Indeed,
he utility of beta-blockers, implantable cardioverter defibrillators,
nd left cervicothoracic sympathetic denervation in this condition
annot be understated (1). Mutations leading to a reduction in the
utward potassium current underlie certain subtypes of LQTS. It
ould therefore seem logical that increasing this outward potas-
ium current might have some therapeutic value. It is noteworthy
hat merely maintaining a serum K well above baseline has the
ffect of reducing the resting corrected QT (QTc) interval, because
f the resultant increase in conductance through both Ikr and IK1
2). Administration of oral potassium to patients with long QT
yndrome type 2 (LQT2) to increase plasma concentration by 1.5
Eq/l above the baseline resulted in a 24% reduction in resting QTc
nterval (from 617  92 ms to 469  23 ms, p  0.004) compared
ith a 4% reduction in control subjects (from 425 25 ms to 410
5 ms, p 0.05) (2). It also normalized QT dispersion and led to an
mproved T-wave morphology and QT-RR relationship (2). The
mprovement in the repolarization abnormality was also seen when
atients with LQT2 were subjected to longer-term oral potassium
dministration (3). An increase in serum K from 4.0  0.3 mEq/l
o 5.2  0.3 mEq/l was found to be safe and resulted in a decrease
n the QTc interval from 526  94 ms to 423  36 ms and
mprovement in both QT dispersion and T-wave morphology (3).
atients with the LQT2 subtype have the highest incidence of a
ardiac event (46%) before age 40 years, and the QTc interval has
een found to be an independent predictor of events (4). This
ould suggest that rectifying the repolarization abnormalities in
hese patients would lead to improved outcomes. Although well-
ontrolled long-term trials are needed to determine its efficacy in
rrhythmia prevention, supplemental potassium seems to be a
romising addition to the treatment armamentarium in congenital
QTS.
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e thank Dr. Kapoor for his interest in our study (1). He
uggests that potassium-raising therapies should be added to
he therapeutic regimen of patients with congenital long QT
yndrome (LQTS) who carry mutations that lead to a reduction
n the outward potassium current. This recommendation is
ased on the results of an early study by Compton et al. (2) that
howed an improvement in several repolarization parameters
fter short-term administration of oral spironolactone and
ntravenous potassium chloride in 7 long QT syndrome type 2
LQT2) patients, and on a more recent study by Etheridge et al.
3) that showed a significant reduction in the duration of the
orrected QT interval in 8 LQT2 genotype carriers after
onger-term (4-week) combined therapy of oral potassium
hloride and spironolactone targeted to increase serum potas-
ium levels to 1.5 mEq/l above baseline. These promising
reliminary data, however, should be interpreted with caution
ecause currently information regarding the clinical efficacy of
otassium-increasing therapies in LQTS patients is not avail-
ble, and an electrocardiographic response may not always
orrelate with clinical response in affected subjects.
After the study by Compton et al. (2), Drs. Mason, Moss, and
heir associates (unpublished data, November 2002) initiated a
ollaborative randomized, placebo-controlled trial of potassium
upplement plus spironolactone versus placebo in LQT2 patients.
he study used conservative potassium doses, as suggested by
ompton et al. (2), but was terminated early because of safety
ssues involving potassium supplement-related hyperkalemia.
hus, until further data regarding the safety and efficacy of this
herapeutic regimen are available, we are reluctant to recommend
hronic potassium-spironolactone supplement in this population.
e do, however, agree with Dr. Kapoor that it is important to
void hypokalemia in LQTS patients, particularly among those
ith the LQT2 genotype, in whom efforts should be made to
aintain serum potassium levels in the 4 to 5 mEq/l range.
